Erratum

Online Summary

Correction to: Ikenberg R, Hertel N, Andrew Moore R, Obradovic M, Baxter G, Conway P, Liedgens H. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ 2012 Mar 28. [Epub ahead of print]

This article refers to:

Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine

Correction to: Ikenberg R, Hertel N, Andrew Moore R, Obradovic M, Baxter G, Conway P, Liedgens H. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ 2012 Mar 28. [Epub ahead of print]

• The authors have been made aware of an error in the equation on page 4. The formula is missing the ‘1’ and should read: 1 − probability of ‘withdrawal due to AEs’ − probability of ‘withdrawal due to lack of efficacy’ − probability of ‘AEs not leading to withdrawal’.

• In addition, ‘tapentadol depot’ should be replaced by ‘tapentadol PR’. The term ‘depot’ is misleading in this context.

This was a formatting error and did not affect the cost-effectiveness outcomes or any of the study results or conclusions.

On behalf of all co-authors,

Robert Ikenberg

IMS Health, Munich, Germany